ERBB2 and breast carcinoma: In this study we sought to determine the incidence of RV dysfunction at the time of cardiotoxicity in women with HER2+ breast cancer receiving treatment with trastuzumab using measurements of fractional area change and myocardial peak systolic longitudinal strain.